Overview
IL17 and IL23 have largely superseded TNF inhibitors in psoriasis. However, they still play a significant role in rheumatology and gastroenterology. We discuss where TNF inhibitors fit in the treatment options for psoriasis and explore TNF inhibitors and their competitors in inflammatory arthritis and inflammatory bowel disease (IBD).
A/Prof Prof Andrew Östör
MD MA MB BS FRACP FRCP FRCP (Edin)
A/Prof Emily Wright
MBBS (Hons) PhD FRACP
A/Prof Chris Baker
MBBS FACD GAICD
Andrew Östör is a Consultant Rheumatologist at Cabrini Medical Centre, A/Prof at Monash University, Melbourne & ANU, Canberra. He is a Principal Investigator at Emeritus Research, Melbourne, Australia. He was formally the Director of the Rheumatology Clinical Research Unit at Addenbrooke’s Hospital, Cambridge UK for 10 years. His research interests currently focus on early inflammatory arthritis, biologic and novel treatments for rheumatic diseases, clinical trials, rheumatic complications of checkpoint inhibitors and disorders of the shoulder joint.
A/Prof Emily Wright is a gastroenterologist and Acting Head of Inflammatory Bowel Diseases at St Vincent’s Hospital Melbourne. She is a principal research (NHMRC) fellow at The University of Melbourne. Emily is an active clinical researcher with interests including the assessment of IBD using intestinal ultrasound, the management of IBD complications including strictures, microbial manipulation and faecal transplantation for the treatment of IBD and the management of IBD during pregnancy.
